Company news
Guardant Health, Inc. news in 2021
Guardant Health, Inc.'s news releases, calls and decks from 2021, newest first.
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
December 16, 2021
Guardant Health Reports Third Quarter 2021 Financial Results
November 3, 2021
Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom
November 2, 2021
Guardant Health Appoints Myrtle Potter to Its Board of Directors
October 19, 2021
Guardant Health to Report Third Quarter Financial Results on November 4, 2021
October 7, 2021
Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal™ Blood Test to Predict Recurrence Across Early-Stage Cancers
October 4, 2021
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
August 4, 2021
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
July 12, 2021
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
June 21, 2021
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
June 17, 2021
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
June 7, 2021
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
May 27, 2021
Guardant360® CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT™ (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 20, 2021
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
May 18, 2021
Guardant Health Reports First Quarter 2021 Financial Results
May 5, 2021
Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer
May 2, 2021
Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
April 29, 2021
Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360® CDx as a Companion Diagnostic for Enhertu® in Advanced Metastatic Non-Small Cell Lung Cancer
April 26, 2021
Guardant Health to Report First Quarter Financial Results on May 6, 2021
April 11, 2021
Guardant Health Receives New York State CLEP Approval for Guardant Reveal Blood Test to Detect and Monitor Residual Disease in Patients with Early-Stage Cancer
March 31, 2021
Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360® CDx Test
March 29, 2021
Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer
March 23, 2021
Guardant360® CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
March 1, 2021
Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021
February 23, 2021
Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer
February 15, 2021
Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
February 3, 2021
Guardant Health and Vall d’Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe
January 17, 2021
Calls in 2021
Decks in 2021
- J.P. Morgan Healthcare Conference 2021
Conference · 34 slides · Jan 11, 2021